ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer

Yang Jin Ji; Chen Hua Jun; Yan Hong Hong; Zhang Xu Chao; Zhou Qing; Su Jian; Wang Zhen; Xu Chong Rui; Huang Yi Sheng; Wang Bin Chao; Yang Xue Ning; Zhong Wen Zhao; Nie Qiang; Liao Ri Qiang; Jiang Ben Yuan; Dong Song; Wu Yi Long*广东省人民医院
Lung Cancer2013-1DOI: 10.1016/j.lungcan.2012.09.016
101被引16阅读
引用收藏
分享

摘要

Background: There is no published overview of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) failure modes in advanced non-small-cell lung cancer (NSCLC). This study aimed to classify the diversity of EGFR-TKI failure, and to investigate the usefulness of clinical modes in subsequent management and prognosis. <br>Methods: One-hundred and twenty consecutive clinical trial patients with EGFR-TKI failure were enrolled as the training set to establish a clinical model based on clinical factors. Another 107 routine patients were enrolled as the validating set according to a Bayes discriminant analysis. EGFR mutations and c-MET amplification were analyzed. Kaplan-Meier survival analysis was used to test the differences among three clinical modes and subsequent management. <br>Results: The duration of disease control, evolution of tumor burden, and clinical symptom were verified as feasible grouping variables. A correct grouping rate achieved 87.9%. The cohort was classified into three groups, as follows: 130 patients with dramatic progression, 42 with gradual progression, and 55 with local progression. Progression-free survivals (PFSs) for the dramatic progression, gradual progression, and local progression groups were 9.3, 12.9, and 9.2 months, respectively (P=0.007). Overall survivals for the groups (OSs) were 17.1, 39.4, and 23.1 months, respectively (P<0.001). TKI continuation was superior to switching chemotherapy in a subsequent setting for gradual progression (39.4 months vs. 17.8 months; P=0.02). The difference of EGFR or c-MET among the three groups was not significant. <br>Conclusions: Clinical modes of EGFR-TKI failure could favor strategies for subsequent treatment and predicting a survival benefit in advanced NSCLC.

学科与关键词

关键词
Non-small-cell lung cancerEpidermal growth factor receptorTyrosine kinase inhibitorFailureMode
被引文献 (1)相关
加载中…
  • Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment
    Yuman, Yu; Yuehong, Wang; Linying, Wu; Xuanli, Xu; Hua, Zhou; Qing, Wang; Jianying, ZhouMedicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2021, 100(5): e23712.

发表信息

论文状态
公开发表
期刊
Lung Cancer
发表日期
2013-01
卷期
第 79 卷, 第 1 期
页码
33-39
DOI
10.1016/j.lungcan.2012.09.016
语言
ENGLISH
期刊等级
Q1
成果收录
SCI
资助标注
National Natural Science Foundation of China [30772531]; Guangdong Science and Technology Department, Industry Technology Research and Development Projects [2011A030400010]; Guangzhou Science and Information Technology Bureau [2011Y2-00014]

作者

  • Y

    Yang Jin Ji (第一作者)

  • C

    Chen Hua Jun

查看全部 17 位作者收起作者
  • Y

    Yan Hong Hong

  • Z

    Zhang Xu Chao

  • Z

    Zhou Qing

  • S

    Su Jian

  • W

    Wang Zhen

  • X

    Xu Chong Rui

  • H

    Huang Yi Sheng

  • W

    Wang Bin Chao

  • Y

    Yang Xue Ning

  • Z

    Zhong Wen Zhao

  • N

    Nie Qiang

  • L

    Liao Ri Qiang

  • J

    Jiang Ben Yuan

  • D

    Dong Song

  • W

    Wu Yi Long (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417